ArticlePrzeglad gastroenterologiczny2015
Diabetes mellitus and the risk of cholangiocarcinoma: an updated meta-analysis.
Article in Przeglad gastroenterologiczny, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Association Between Metabolic Syndrome and Long-Term Prognosis in Patients with Perihilar Cholangiocarcinoma Treated with Curative-Intent Resection: A Multicenter Study.Annals of surgical oncology · 2026Article
- Epidemiologic transition of biliary tract cancers in an endemic region of Korea: insights from a regional cancer center cohort.BMC gastroenterology · 2026Observational
- Ontology development and use for cholangiocarcinoma risk factors and predictions: a term enrichment data analysis and machine learning classification.Journal of biomedical semantics · 2026Article
- Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database.Diseases (Basel, Switzerland) · 2025Article
- Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.Cancers · 2024Review
- Spatial analysis of cholangiocarcinoma in relation to diabetes mellitus and Opisthorchis viverrini infection in Northeast Thailand.Scientific reports · 2024Article
- Current view of liver cancer cell-of-origin and proposed mechanisms precluding its proper determination.Cancer cell international · 2023Review
- Insulin therapy and biliary tract cancer: insights from real-world data.Endocrine connections · 2022Article
- Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide.Middle East journal of digestive diseases · 2022Review
- Widening Health Disparities: Increasing Cholangiocarcinoma Incidence in an Underserved Population.Gastro hep advances · 2022Article
- Association of comorbidity between Opisthorchis viverrini infection and diabetes mellitus in the development of cholangiocarcinoma among a high-risk population, northeastern Thailand.PLoS neglected tropical diseases · 2021Article
- Identification of prognostic factors for intrahepatic cholangiocarcinoma using long non-coding RNAs-associated ceRNA network.Cancer cell international · 2020Article
- Atypical presentation of intrahepatic cholangiocarcinoma---Fever and ascites in a postpartum lady.Journal of family medicine and primary care · 2019Article
- Molecular Pathogenesis of Cholangiocarcinoma.BMC cancer · 2019Review
- Diabetes and the Pancreatobiliary Diseases.Current treatment options in gastroenterology · 2017Review
- New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA number of studies have shown that diabetes mellitus is implicated in susceptibility to several cancers. However, the relationship between diabetes and cholangiocarcinoma remain unclear.
aimTo quantitatively assess the relationship between diabetes and incidence of cholangiocarcinoma in cohort and case-control studies. MATERIAL AND
methodsA literature search was performed for entries from 1996 to 2014 using the PubMed and EMBASE databases. Studies were included if they reported odds ratios (OR) and corresponding 95% CI of cholangiocarcinoma with respect to diabetes mellitus.
resultsTwenty studies met the inclusion criteria, which included fifteen case-control studies and five cohort studies from Asia (n = 11), the United States (n = 5), and Europe (n = 4). Compared with individuals without diabetes, the pooled OR of cholangiocarcinoma was 1.74 (95% CI: 1.62-1.87, p = 0.568 for heterogeneity) for patients with diabetes, ICC (summary RR, 1.93; 95% CI: 1.65-2.25; p = 0.037 for heterogeneity), and ECC (summary RR, 1.66; 95% CI: 1.39-1.98; p = 0.001 for heterogeneity). The funnel plot revealed no evidence for publication bias concerning diabetes and the risk of CC (including ICC and ECC).
conclusionsThe findings from this meta-analysis suggest that diabetes may increase the risk of cholangiocarcinoma. This relationship needs to be confirmed by further follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.